PDF(Pubmed)
Abstract：
UNASSIGNED: Providing data on the superior efficacy of vancomycin administered based on the area under the curve over 24 hours to the minimum inhibitory concentration of vancomycin (AUC24/MIC) is crucial. However, data on dosing and monitoring of vancomycin pharmacokinetics in the pediatric population are limited. Previous findings have showed that intermittent infusion of vancomycin (IIV) may not achieve the desired levels, continous infusions of vancomycin (CIV) reach the desired serum concentration faster than IIV and are associated with reduced nephrotoxicity.
UNASSIGNED: This study aimed to compare the serum concentrations, AUC24, clinical variables, and adverse effects of two vancomycin administration methods in the pediatric population.
UNASSIGNED: This study was a double-blind, randomized, controlled clinical trial conducted at a tertiary children\'s teaching hospital. Inclusion criteria were age between 2 months and 15 years and weight less than 67 kilograms, with exclusion criteria including renal impairment. Participants were divided into CIV and IIV groups following distinct administration protocols. Demographic, clinical, and laboratory data, including vancomycin serum concentrations, were compiled. Assessments included pediatric mortality risk, pediatric sequential organ failure assessment, and regular temperature monitoring. Pharmacokinetic analysis was conducted using Monolix software 2023R1. Primary endpoints were vancomycin serum levels and AUC24 between cohorts on day three, with nephrotoxicity and additional adverse drug responses evaluated.
UNASSIGNED: Sixty-eight patients in the pediatric intensive care unit (PICU) were allocated to either CIV (33) or IIV (35) for vancomycin treatment. In the CIV group, 82% of patients achieved an AUC24 ≥ 400 mg.h/L, compared to 23% in the IIV group. Continuous infusions of vancomycin demonstrated a greater AUC24 (587.7 ± 184.4 mg.h/L vs. 361.9 ± 113.2 mg.h/L, P < 0.05) compared to IIV. Two cases of nephrotoxicity were reported, one in each group, with mortality and adverse events being comparable between the two groups.
UNASSIGNED: This study demonstrated that continuous vancomycin infusion has a higher success rate in safely achieving therapeutic vancomycin levels in PICU patients compared to intermittent vancomycin infusion.
UNASSIGNED: This study aimed to compare the serum concentrations, AUC24, clinical variables, and adverse effects of two vancomycin administration methods in the pediatric population.
UNASSIGNED: This study was a double-blind, randomized, controlled clinical trial conducted at a tertiary children\'s teaching hospital. Inclusion criteria were age between 2 months and 15 years and weight less than 67 kilograms, with exclusion criteria including renal impairment. Participants were divided into CIV and IIV groups following distinct administration protocols. Demographic, clinical, and laboratory data, including vancomycin serum concentrations, were compiled. Assessments included pediatric mortality risk, pediatric sequential organ failure assessment, and regular temperature monitoring. Pharmacokinetic analysis was conducted using Monolix software 2023R1. Primary endpoints were vancomycin serum levels and AUC24 between cohorts on day three, with nephrotoxicity and additional adverse drug responses evaluated.
UNASSIGNED: Sixty-eight patients in the pediatric intensive care unit (PICU) were allocated to either CIV (33) or IIV (35) for vancomycin treatment. In the CIV group, 82% of patients achieved an AUC24 ≥ 400 mg.h/L, compared to 23% in the IIV group. Continuous infusions of vancomycin demonstrated a greater AUC24 (587.7 ± 184.4 mg.h/L vs. 361.9 ± 113.2 mg.h/L, P < 0.05) compared to IIV. Two cases of nephrotoxicity were reported, one in each group, with mortality and adverse events being comparable between the two groups.
UNASSIGNED: This study demonstrated that continuous vancomycin infusion has a higher success rate in safely achieving therapeutic vancomycin levels in PICU patients compared to intermittent vancomycin infusion.
摘要：
■提供基于24小时内的曲线下面积给予万古霉素至万古霉素的最小抑制浓度（AUC24/MIC）的优异功效的数据至关重要。然而,儿科人群中万古霉素药动学的给药和监测数据有限.先前的研究结果表明，间歇输注万古霉素（IIV）可能无法达到所需的水平，连续输注万古霉素（CIV）比IIV更快地达到所需的血清浓度，并且与降低的肾毒性有关。
■这项研究旨在比较血清浓度，AUC24，临床变量，以及两种万古霉素给药方法在儿科人群中的不良反应。
■这项研究是双盲的，随机化，在三级儿童教学医院进行的对照临床试验。纳入标准是年龄在2个月至15岁之间，体重低于67公斤，排除标准包括肾损害。根据不同的给药方案，将参与者分为CIV和IIV组。人口统计,临床,和实验室数据，包括万古霉素血清浓度,被编译。评估包括儿科死亡风险，儿科序贯器官衰竭评估，定期监测温度。使用Monolix软件2023R1进行药代动力学分析。主要终点是第三天队列之间的万古霉素血清水平和AUC24，评估肾毒性和其他药物不良反应。
■儿科重症监护病房（PICU）的68名患者被分配到接受万古霉素治疗的CIV（33）或IIV（35）。在CIV组中，82%的患者达到AUC24≥400mg。h/L,与IIV组的23%相比。连续输注万古霉素显示出更高的AUC24（587.7±184.4mg。h/Lvs.361.9±113.2毫克。h/L,P<0.05)与IIV相比。报告了2例肾毒性，每组一个,两组之间的死亡率和不良事件具有可比性。
■该研究表明，与间歇性万古霉素输注相比，连续万古霉素输注在PICU患者中安全达到治疗性万古霉素水平方面具有更高的成功率。
■这项研究旨在比较血清浓度，AUC24，临床变量，以及两种万古霉素给药方法在儿科人群中的不良反应。
■这项研究是双盲的，随机化，在三级儿童教学医院进行的对照临床试验。纳入标准是年龄在2个月至15岁之间，体重低于67公斤，排除标准包括肾损害。根据不同的给药方案，将参与者分为CIV和IIV组。人口统计,临床,和实验室数据，包括万古霉素血清浓度,被编译。评估包括儿科死亡风险，儿科序贯器官衰竭评估，定期监测温度。使用Monolix软件2023R1进行药代动力学分析。主要终点是第三天队列之间的万古霉素血清水平和AUC24，评估肾毒性和其他药物不良反应。
■儿科重症监护病房（PICU）的68名患者被分配到接受万古霉素治疗的CIV（33）或IIV（35）。在CIV组中，82%的患者达到AUC24≥400mg。h/L,与IIV组的23%相比。连续输注万古霉素显示出更高的AUC24（587.7±184.4mg。h/Lvs.361.9±113.2毫克。h/L,P<0.05)与IIV相比。报告了2例肾毒性，每组一个,两组之间的死亡率和不良事件具有可比性。
■该研究表明，与间歇性万古霉素输注相比，连续万古霉素输注在PICU患者中安全达到治疗性万古霉素水平方面具有更高的成功率。
